Given its prevalence, evidence has supported SF3B1-mutant MDS being its own subtype within the family of MDS, as discovery of the mutation has important clinical implication in risk stratification and therapeutic decision-making. The gene discussed is SF3B1; the disease is myelodysplastic syndrome.